
Faculty, Staff and Student Publications
Publication Date
10-5-2022
Journal
Frontiers in Pharmacology
Abstract
Medicinal cannabis has shown promise for the symptomatic treatment of Parkinson's disease (PD), but patient exposure to whole plant mixtures may be undesirable due to concerns around safety, consistency, regulatory issues, and psychoactivity. Identification of a subset of components responsible for the potential therapeutic effects within cannabis represents a direct path forward for the generation of anti-PD drugs. Using an
Keywords
Parkinson’s disease, cannabinoids, zebrafish, dopamine, neuroprotection, movement disorder, cannabis, cannabidiol
DOI
10.3389/fphar.2022.907579
PMID
36278152
PMCID
PMC9586206
PubMedCentral® Posted Date
October 2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Pharmacy and Pharmaceutical Sciences Commons, Plants Commons
Comments
Supplementary Material
PMID: 36278152